The companies said their partnership will allow pharmaceutical partners to measure both ctDNA and CTC biomarkers from a single blood draw when conducting drug trials.
Inivata's Radar assay will be used to monitor circulating tumor DNA from multiple tumor types in trial participants following treatment with Maverick's MVC-101 candidate.
Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.
Stanford and Memorial Sloan Kettering researchers have developed a multi-modal and multi-timepoint biomarker approach to predict therapeutic benefit in lung cancer cases.
The firm said that it has secured coverage for about 100 million lives for its targeted NGS liquid biopsy test in the US between Medicare and private payors.
In PLOS this week: no enrichment of rare variants among Parkinson's disease patients in associated genes, circulating tumor DNA helps guide metastatic breast cancer patient management, and more.
The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.
Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.
